Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment
25 oct. 2022 10h00 HE
|
Zhittya Genesis Medicine Inc
Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...
Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease
25 oct. 2022 07h15 HE
|
Sinaptica Therapeutics
Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham...
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
19 oct. 2022 04h00 HE
|
AKAMPION
- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
17 oct. 2022 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
11 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Red Tree Venture Capital Announces Closing of $272 Million Inaugural Fund
06 oct. 2022 06h00 HE
|
Red Tree Venture Capital
West Coast-Centric, Early Stage-Biased Venture Capital Firm Focused on Investing in Life Science Innovation Emerging from Premier West Coast Academic and Research Institutions Led by an Accomplished...
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
04 oct. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
29 sept. 2022 16h01 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
27 sept. 2022 12h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health
27 sept. 2022 09h00 HE
|
ADM Diagnostics Inc
NORTHBROOK, Ill., Sept. 27, 2022 (GLOBE NEWSWIRE) -- ADM Diagnostics, Inc. (ADMdx) has been awarded a two-year $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the...